Kineta (STU:J75) Debt-to-Equity : -0.17 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kineta Debt-to-Equity?

Kineta's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.87 Mil. Kineta's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.14 Mil. Kineta's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €-5.89 Mil. Kineta's debt to equity for the quarter that ended in Mar. 2024 was -0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kineta's Debt-to-Equity or its related term are showing as below:

STU:J75' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.9 Med: -0.54 Max: 0.6
Current: -0.17

During the past 4 years, the highest Debt-to-Equity Ratio of Kineta was 0.60. The lowest was -11.90. And the median was -0.54.

STU:J75's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs STU:J75: -0.17

Kineta Debt-to-Equity Historical Data

The historical data trend for Kineta's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Debt-to-Equity Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-1.13

-1.79

0.51

0.46

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial							-11.86	0.25	0.60	0.46	-0.17

Competitive Comparison of Kineta's Debt-to-Equity

For the Biotechnology subindustry, Kineta's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kineta's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kineta's Debt-to-Equity falls into.

Kineta Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kineta's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.07	+	0.138)	/	2.65
	=	0.46

Kineta's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.872	+	0.138)	/	-5.889
	=	-0.17

Kineta (STU:J75) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kineta Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kineta's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta (STU:J75) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (STU:J75) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KA:USA

Address

219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Kineta (STU:J75) Headlines

No Headlines